1 week Ago By ABMN Staff
Norges Bank bought a new stake in shares of Vera Therapeutics, Inc. ( NASDAQ:VERA – Free Report ) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 48,593 shares of the company’s stock, valued at approximately $2,055,000.
Norges Bank owned 0.08% of Vera Therapeutics as of its most recent SEC filing. Several other institutional investors and hedge funds have also recently bought and sold shares of the company.
SG Americas Securities LLC boosted its position in Vera Therapeutics by 116.7% during the 4th quarter. SG Americas Securities LLC now owns 20,270 shares of the company’s stock worth $857,000 after acquiring an additional 10,916 shares during the period.
Lord Abbett & CO. LLC lifted its holdings in Vera Therapeutics by 41.1% in the third quarter.
Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock worth $18,830,000 after purchasing an additional 124,197 shares during the period. Barclays PLC lifted its holdings in Vera Therapeutics by 94.
1% in the third quarter. Barclays PLC now owns 85,395 shares of the company’s stock worth $3,774,000 after purchasing an additional 41,394 shares during the period. Geode Capital Management LLC grew its position in Vera Therapeutics by 2.
1% in the 3rd quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company’s stock valued at $44,415,000 after buying an additional 20,223 shares in the last quarter. Finally, Raymond James Financial Inc.
acquired a new position in Vera Therapeutics during the 4th quarter valued at about $2,948,000. Institutional investors own 99.21% of the company’s stock.
Vera Therapeutics Stock Performance Shares of NASDAQ VERA opened at $22.43 on Friday. Vera Therapeutics, Inc.
has a 52-week low of $18.53 and a 52-week high of $51.61.
The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -8.59 and a beta of 1.
28. The company has a quick ratio of 13.76, a current ratio of 13.
76 and a debt-to-equity ratio of 0.17. The stock’s fifty day simple moving average is $27.
58 and its 200 day simple moving average is $37.27. Analyst Ratings Changes A number of analysts have recently weighed in on VERA shares.
JPMorgan Chase & Co. reduced their price target on shares of Vera Therapeutics from $77.00 to $71.
00 and set an “overweight” rating for the company in a research note on Tuesday, March 4th. The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research note on Tuesday, January 28th. They set a “buy” rating and a $58.
00 price target for the company. Wolfe Research started coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.
00 price target on the stock. Finally, Guggenheim upped their price objective on Vera Therapeutics from $59.00 to $61.
00 and gave the company a “buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $64.
67. Check Out Our Latest Stock Analysis on VERA Vera Therapeutics Profile ( Free Report ) Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
Further Reading Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. ( NASDAQ:VERA – Free Report ).
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
